𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro

✍ Scribed by Paul M.J. Clement; Hartmut M. Hanauske-Abel; Edith C. Wolff; Hynda K. Kleinman; Myung Hee Park


Book ID
102862481
Publisher
John Wiley and Sons
Year
2002
Tongue
French
Weight
516 KB
Volume
100
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The hypusine biosynthetic steps represent novel targets for intervention in cell proliferation. Hypusine is a rare amino acid, formed posttranslationally in one cellular protein, eIF5A, and is essential for cell proliferation. Deoxyhypusine hydroxylase, the metalloenzyme catalyzing the final step in hypusine biosynthesis, and prolyl 4‐hydroxylase, a non‐heme iron enzyme critical for collagen processing, can be inhibited by small chelating molecules that target their essential metal atom. We examined the effects of 5 compounds (ciclopirox, deferiprone, deferoxamine, mimosine and 2,2′‐dipyridyl) on these protein hydroxylases in HUVECs, on cell proliferation and on angiogenesis using 2 model assays: tube‐like vessel formation on Matrigel and the chick aortic arch sprouting assay. These compounds inhibited cellular deoxyhypusine hydroxylase in a concentration‐dependent manner, but their efficacy varied widely in the following order: ciclopirox→ deferoxamine→2,2′‐dipyridyl→deferiprone→mimosine (IC~50~ 5–200 μM). Inhibition of DNA synthesis, following the same order (IC~50~ 10–450 μM), correlated with G~1~ arrest of the cell cycle. These compounds also inhibited proline hydroxylation and maturation of collagen in HUVECs and caused inhibition of angiogenesis in vitro. Of the compounds tested, ciclopirox was by far the most effective inhibitor of HUVEC proliferation and angiogenesis. The strong antiangiogenic activity of this readily available antifungal drug along with its antiproliferative effects suggests a new potential application for ciclopirox in the treatment of solid tumors. Published 2002 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Vascular endothelial growth factor (VEGF
✍ Michael S. Pepper; Stefano J. Mandriota; Michael Jeltsch; Vijay Kumar; Kari Alit 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 689 KB

Vascular endothelial growth factor-C (VEGF-C) is a recently characterized member of the VEGF family of angiogenic polypeptides. We demonstrate here that VEGF-C is angiogenic in vitro when added to bovine aortic or lymphatic endothelial (BAE and BLE) cells but has little or no effect on bovine microv